157. Sturge-Weber syndrome
8 clinical trials, 11 drugs (DrugBank: 4 drugs), 5 drug target genes, 62 drug target pathways
Searched query = "Sturge-Weber syndrome", "Síndrome de Sturge-Weber"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04447846 (ClinicalTrials.gov) | October 14, 2019 | 10/10/2019 | Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome | Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: A Phase II Trial | Sturge-Weber Syndrome | Drug: Cannabidiol | Anne Comi, MD | GW Pharmaceuticals Ltd.;Faneca 66 Foundation | Recruiting | 3 Years | 50 Years | All | 10 | Phase 2 | United States |
| 2 | NCT02332655 (ClinicalTrials.gov) | December 2014 | 5/1/2015 | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Sturge-Weber Syndrome | Drug: Cannabidiol | Anne Comi, MD | GW Pharmaceuticals Ltd.;Faneca 66 Foundation | Active, not recruiting | 1 Month | 45 Years | All | 5 | Phase 1;Phase 2 | United States |